Macrophage phenotype transition

Macrophage phenotype transition, or macrophage polarization, is a dynamic biological process where macrophages alter their functional and morphological characteristics in response to local microenvironmental cues (Nature Reviews Immunology, 2017). Broadly classified into the M1 (classical/pro-inflammatory) and M2 (alternative/anti-inflammatory) phenotypes, this transition allows macrophages to play diverse roles ranging from pathogen clearance to tissue remodeling (Cell, 2014). In the tumor microenvironment, macrophages often undergo a transition to a 'tumor-associated macrophage' (TAM) phenotype that resembles the M2 state, facilitating immunosuppression, angiogenesis, and tumor metastasis (Science Signaling, 2016). Conversely, an inability to resolve the pro-inflammatory M1 state can lead to chronic tissue damage and autoimmune conditions (Journal of Clinical Investigation, 2015). Therapeutic strategies currently focus on 'reprogramming' or 'repolarizing' these cells rather than depleting them entirely. Drugs like pexidartinib (a CSF1R inhibitor) and eganelisib (a PI3K-gamma inhibitor) are designed to block signaling pathways that maintain the suppressive M2-like state, thereby restoring the macrophages' ability to stimulate a T-cell-mediated anti-tumor immune response (Frontiers in Immunology, 2021). Because this process involves multiple redundant pathways, targeting the transition often requires combination therapies to achieve sustained therapeutic efficacy (Nature Communications, 2020).

Other names

Macrophage polarizationMacrophage phenotypic switchingM1/M2 polarizationMacrophage plasticityM1/M2 switching

Drugs modulate this transition by inhibiting or activating specific molecular checkpoints—such as CSF1R, PI3K-gamma, STAT3, or TLRs—that act as switches for macrophage activation states. By targeting these components, therapeutics aim to shift macrophages from a pro-tumorigenic, immunosuppressive M2-like state toward a pro-inflammatory, anti-tumor M1-like state, or vice versa in the context of chronic inflammatory diseases.